Supporting Information

Cobalt(III)-Catalyzed C-C Coupling of Arenes with

7-Oxabenzonorbornadiene and 2-Vinyloxirane via C-H Activation

Lingheng Kong,^{†‡} Songjie Yu,[†] Guodong Tang,[†] He Wang,[†] Xukai Zhou,^{†‡} Xingwei $Li^{*^{\dagger}}$

[†]Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China

[‡]University of Chinese Academy of Sciences, Beijing 100049, China

Email: xwli@dicp.ac.cn

Content

I.	General	S2
II.	General procedures for the synthesis of compound 3	S2
III.	General procedures for the synthesis of compound 4	S9
IV.	Mechanistic Studies	S18
	1. The experiment of H/D exchange	S18
	2. Competitive Experiment	S20
V.	References	S21
VI.	NMR Spectra	S22

I. General

All chemicals were obtained from commercial sources and were used as received unless otherwise noted. *N*-pyrimidinylindoles,¹ 7-Oxabenzonorbornadienes,² [Cp*CoCl₂]₂,³ [Cp*Co(MeCN)₃](SbF₆)₂⁴ were prepared by following literature reports. All reactions were carried out using Schlenk techniques or in an N₂-filled glovebox. NMR Spectra were recorded on a 400 MHz NMR spectrometer in the solvent indicated. The chemical shift is given in dimensionless δ values and is frequency referenced relative to TMS in ¹H and ¹³C NMR spectroscopy. HRMS data were obtained on a Thermo Scientific LTQ Orbitrap Discovery spectrometer (Bremen, Germany). Column chromatography was performed on silica gel (300-400 mesh) using Ethyl acetate (EA)/petroleum ether (PE).

II. General procedures for the synthesis of compound 3

Reaction conditions: indole (0.2 mmol), 7-oxabenzonorbornadiene (0.4 mmol), $[Cp*CoCl_2]_2$ (5 mol %), AgSbF₆ (30 mol %), HOAc (2 equiv), and DCE (2 mL) were charged into the pressure tube. The reaction mixture was stirred under N₂ at 50 °C for 12 h. After the solvent was removed under reduced pressure, the residue was purified by silica gel chromatography using PE/EA to afford the product **3**.



2-(Naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (3aa)

3aa was obtained according to the general procedure in 86% yield (52.1 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, J = 4.5 Hz, 2H), 8.20 (d, J = 7.9 Hz, 1H), 7.88 (s, 1H), 7.79 – 7.76 (m, 2H), 7.68 (t, J = 9.0 Hz, 2H), 7.49 – 7.40 (m, 2H), 7.32 – 7.22 (m, 3H), 7.03 (t, J = 4.9 Hz, 1H), 6.90 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 158.2, 140.6, 138.3, 133.4, 132.5, 131.6, 129.5, 128.2, 127.7, 127.5, 126.7, 126.6, 126.3, 126.1, 123.7, 122.3, 120.8, 117.6, 113.0, 108.9. HRMS: [M + H]⁺ calculated for C₂₂H₁₆N₃⁺: 322.1339, found: 322.1341.



4-Methyl-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (**3ba**)

3ba was obtained according to the general procedure in 77% yield (51.7 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J = 4.6 Hz, 2H), 8.02 (d, J = 8.3 Hz, 1H), 7.89 (s, 1H), 7.79 – 7.76 (m, 2H), 7.68 (d, J = 8.4 Hz, 1H), 7.48 – 7.39 (m, 2H), 7.27 (d, J = 8.3 Hz, 1H), 7.21 (t, J = 7.7 Hz, 1H), 7.05 (d, J = 7.1 Hz, 1H), 7.01 (t, J = 4.6 Hz, 1H), 6.94 (s, 1H), 2.61 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 158.28, 140.0, 138.1, 133.4, 132.5, 131.8, 130.2, 129.2, 128.2, 127.7, 127.5, 126.6, 126.3, 126.0, 123.9, 122.6, 117.6, 110.6, 107.4, 18.8. HRMS: [M + H]⁺ calculated for C₂₃H₁₈N₃⁺: 336.1495, found: 336.1497.



4-Methoxy-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (3ca)

3ca was obtained according to the general procedure in 70% yield (49.2 mg). white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, J = 4.7 Hz, 2H), 7.86 (s, 1H), 7.79 – 7.74 (m, 3H), 7.67 (d, J = 8.5 Hz, 1H), 7.52 – 7.37 (m, 2H), 7.31 – 7.17 (m, 2H), 7.09 – 6.97 (m, 2H), 6.67 (d, J = 7.8 Hz, 1H), 3.97 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.31, 158.3, 153.2, 139.6, 139.1, 133.4, 132.4, 131.6, 128.2, 127.7, 127.4, 126.6, 126.6, 126.2, 126.0, 124.6, 120.0, 117.7, 106.2, 105.8, 102.4, 55.5. HRMS: [M + H]⁺ calculated for C₂₃H₁₈N₃O⁺: 352.1444, found: 352.1448.



4-(Benzyloxy)-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (3da)

3da was obtained according to the general procedure in 83% yield (70.9 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.61 (d, *J* = 4.8 Hz, 2H), 7.87 (s, 1H), 7.80 – 7.74 (m, 3H), 7.68 (d, *J* = 8.5 Hz, 1H), 7.52 (d, *J* = 7.3 Hz, 2H), 7.47 – 7.36 (m, 4H), 7.34 – 7.30 (m, 1H), 7.26 (d, *J* = 8.5 Hz, 1H), 7.23 – 7.17 (m, 1H), 7.11 (s, 1H), 7.05 (t, *J* = 4.8 Hz, 1H), 6.74 (d, *J* = 7.9 Hz, 1H), 5.26 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 152.3, 139.7, 139.1, 137.5, 133.4, 132.4, 131.6, 128.6, 128.2, 127.9, 127.7, 127.5, 127.4, 126.6, 126.57, 126.2, 126.0, 124.5, 120.4, 117.7, 106.4, 106.1, 103.9, 70.1. One signal is missing due to overlap. HRMS: [M + H]⁺ calculated for C₂₉H₂₂N₃O⁺: 428.1757, found: 428.1754.



Methyl 2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole-4-carboxylate (**3ea**) **3ea** was obtained according to the general procedure in 80% yield (60.1 mg). white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 4.6 Hz, 2H), 8.37 (d, *J* = 8.2 Hz, 1H), 8.02 (d, *J* = 7.5 Hz, 1H), 7.94 (s, 1H), 7.85 – 7.74 (m, 2H), 7.70 (d, *J* = 8.5 Hz, 1H), 7.62 (s, 1H), 7.47 (d, *J* = 4.1 Hz, 2H), 7.33 (t, *J* = 7.9 Hz, 1H), 7.27 (d, *J* = 8.3 Hz, 1H), 7.09 (t, *J* = 4.6 Hz, 1H), 4.01 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.8, 158.5, 158.0, 142.7, 139.0, 133.4, 132.7, 131.1, 129.3, 128.3, 127.7, 127.6, 127.3, 126.5, 126.4, 126.3, 125.4, 122.9, 121.6, 118.2, 117.7, 109.4, 52.0. HRMS: [M + H]⁺ calculated for C₂₄H₁₈N₃O₂⁺: 380.1394, found: 380.1393.



4-Bromo-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (3fa)

3fa was obtained according to the general procedure in 84% yield (67.0 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, J = 4.7 Hz, 2H), 8.11 (d, J = 8.3 Hz, 1H), 7.90 (s, 1H), 7.80 – 7.77 (m, 2H), 7.70 (d, J = 8.5 Hz, 1H), 7.54 – 7.44 (m, 2H), 7.41 (d, J = 7.7 Hz, 1H), 7.25 (d, J = 9.3 Hz, 1H), 7.15 (t, J = 8.0 Hz, 1H), 7.09 (t, J = 4.7 Hz, 1H), 6.97 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 158.0, 141.3, 138.4, 133.3, 132.6, 131.0, 130.0, 128.2, 127.7, 127.6, 127.0, 126.4, 126.37, 126.3, 125.1, 124.5, 118.1, 114.5, 112.2, 108.3. HRMS: [M + H]⁺ calculated for C₂₂H₁₅BrN₃⁺: 400.0444, found: 400.0447.



5-Methyl-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (**3ga**)

3ga was obtained according to the general procedure in 82% yield (55.0 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, J = 4.8 Hz, 2H), 8.10 (d, J = 8.5 Hz, 1H), 7.88 (s, 1H), 7.78 (dd, J = 9.5, 6.5 Hz, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.46 – 7.44 (m, 3H), 7.27 (dd, J = 8.5, 1.7 Hz, 1H), 7.12 (dd, J = 8.5, 1.2 Hz, 1H), 7.04 (t, J = 4.8 Hz, 1H), 6.83 (s, 1H), 2.47 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 158.2, 140.5, 136.6, 133.4, 132.5, 131.8, 131.6, 129.7, 128.2,

127.7, 127.4, 126.6, 126.5, 126.2, 126.0, 125.2, 120.6, 117.4, 112.8, 108.8, 21.4. HRMS: $[M + H]^+$ calculated for $C_{23}H_{18}N_3^+$: 336.1495, found: 336.1496.



5-Methoxy-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (3ha)

3ha was obtained according to the general procedure in 58% yield (40.7 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, J = 4.8 Hz, 2H), 8.14 (d, J = 9.0 Hz, 1H), 7.88 (s, 1H), 7.79 (dd, J = 8.9, 4.9 Hz, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.48 – 7.43 (m, 2H), 7.27 (d, J = 8.5 Hz, 1H), 7.12 (d, J = 2.2 Hz, 1H), 7.02 (t, J = 4.7 Hz, 1H), 6.94 (dd, J = 9.0, 2.3 Hz, 1H), 6.83 (s, 1H), 3.88 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 155.7, 141.1, 133.3, 133.2, 132.5, 131.8, 130.1, 128.2, 127.7, 127.4, 126.6, 126.6, 126.2, 126.0, 117.4, 114.1, 113.0, 108.9, 102.7, 55.8. One signal is missing due to overlap. HRMS: [M + H]⁺ calculated for C₂₃H₁₈N₃O⁺: 352.1444, found: 352.1448.



Methyl 2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole-5-carboxylate (**3ia**)

3ia was obtained according to the general procedure in 75% yield (56.5 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.61 (d, J = 4.8 Hz, 2H), 8.41 (s, 1H), 8.17 (d, J = 8.8 Hz, 1H), 8.00 (d, J = 8.8 Hz, 1H), 7.86 (s, 1H), 7.80 – 7.76 (m, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.47 – 7.44 (m, 2H), 7.27 – 7.19 (m, 1H), 7.09 (t, J = 4.8 Hz, 1H), 6.95 (s, 1H), 3.94 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.9, 158.5, 157.9, 142.0, 140.7, 133.3, 132.7, 131.0, 129.1, 128.2, 127.7, 127.6, 127.0, 126.44, 126.4, 126.3, 125.0, 124.2, 123.3, 118.2, 112.7, 109.0, 52.1. HRMS: [M + H]⁺ calculated for C₂₄H₁₈N₃O₂⁺: 380.1394, found: 380.1397.



5-Fluoro-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (3ja)

3ja was obtained according to the general procedure in 73% yield (49.5 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.60 (d, J = 4.8 Hz, 2H), 8.17 – 8.14 (m, 1H), 7.88 (s, 1H), 7.79 (dd, J = 9.5, 6.3 Hz, 2H), 7.70 (d, J = 8.5 Hz, 1H), 7.52 – 7.42 (m, 2H), 7.30 (dd, J = 8.9, 2.4 Hz, 1H),

7.28 – 7.23 (m, 1H), 7.08 – 7.00 (m, 2H), 6.85 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 158.31, 158.3, 158.0, 142.1, 133.6 (d, $J_{C-F} = 203.9$ Hz), 133.3, 131.3, 130.0 (d, $J_{C-F} = 10.2$ Hz), 128.2, 127.7, 127.5, 126.8, 126.5, 126.3, 126.2, 117.7, 114.1 (d, $J_{C-F} = 9.3$ Hz), 111.5 (d, $J_{C-F} = 25.4$ Hz), 108.5 (d, $J_{C-F} = 4.2$ Hz), 105.9, 105.7. HRMS: [M + H]⁺ calculated for C₂₂H₁₅FN₃⁺: 340.1245, found: 340.1249.



5-Chloro-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (3ka)

3ka was obtained according to the general procedure in 70% yield (49.8 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, J = 4.5 Hz, 2H), 8.12 (d, J = 8.8 Hz, 1H), 7.86 (s, 1H), 7.78 – 7.76 (m, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.61 (s, 1H), 7.47 – 7.45 (m, 2H), 7.24 (d, J = 8.4 Hz, 2H), 7.06 – 7.05 (m, 1H), 6.81 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 157.9, 141.9, 136.5, 133.3, 132.6, 131.2, 130.5, 128.2, 127.7, 127.5, 126.9, 126.44, 126.4, 126.3, 123.8, 120.1, 117.9, 114.3, 108.0. One signal is missing due to overlap. HRMS: [M + H]⁺ calculated for C₂₂H₁₅ClN₃⁺: 356.0949, found: 356.0950.



6-Methyl-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (3la)

3la was obtained according to the general procedure in 62% yield (41.1 mg). white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, *J* = 4.8 Hz, 2H), 8.00 (s, 1H), 7.85 (s, 1H), 7.78 – 7.75 (m, 2H), 7.67 (d, *J* = 8.5 Hz, 1H), 7.54 (d, *J* = 7.9 Hz, 1H), 7.46 – 7.41 (m, 2H), 7.27 – 7.24 (m, 1H), 7.08 (d, *J* = 7.9 Hz, 1H), 7.02 (t, *J* = 4.8 Hz, 1H), 6.86 (s, 1H), 2.50 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 158.26, 140.0, 138.7, 133.7, 133.4, 132.4, 131.8, 128.2, 127.7, 127.4, 127.3, 126.6, 126.5, 126.2, 125.9, 123.9, 120.4, 117.5, 112.9, 108.8, 22.2. HRMS: [M + H]⁺ calculated for C₂₃H₁₈N₃⁺: 336.1495, found: 336.1498.



Methyl 2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole-6-carboxylate (**3ma**) **3ma** was obtained according to the general procedure in 67% yield (50.1 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.84 (s, 1H), 8.64 (d, J = 4.8 Hz, 2H), 7.95 (dd, J = 8.2, 1.3 Hz, 1H), 7.88 (s, 1H), 7.80 – 7.76 (m, 2H), 7.69 (t, J = 8.6 Hz, 2H), 7.51 – 7.42 (m, 2H), 7.28 – 7.21 (m, 1H), 7.09 (t, J = 4.8 Hz, 1H), 6.92 (s, 1H), 3.93 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.1, 158.6, 157.8, 143.7, 137.6, 133.3, 133.1, 132.8, 130.9, 128.3, 127.8, 127.7, 127.2, 126.5, 126.4, 126.4, 125.2, 123.4, 120.4, 118.2, 115.1, 108.4, 52.1. HRMS: [M + H]⁺ calculated for C₂₄H₁₈N₃O₂⁺: 380.1394, found: 380.1397.



6-Chloro-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (3na)

3na was obtained according to the general procedure in 74% yield (52.6 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, *J* = 4.8 Hz, 2H), 8.24 (s, 1H), 7.85 (s, 1H), 7.79 – 7.75 (m, 2H), 7.68 (d, *J* = 8.5 Hz, 1H), 7.54 (d, *J* = 8.3 Hz, 1H), 7.48 – 7.42 (m, 2H), 7.25 – 7.21 (m, 2H), 7.05 (t, *J* = 4.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 157.8, 141.3, 138.5, 133.3, 132.6, 131.2, 129.5, 128.2, 128.0, 127.7, 127.5, 126.7, 126.4, 126.4, 126.2, 122.9, 121.5, 117.9, 113.4, 108.5. HRMS: [M + H]⁺ calculated for C₂₂H₁₅ClN₃⁺: 356.0949, found: 356.0951.



7-Ethyl-2-(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (30a)

30a was obtained in the condition of indole (0.2 mmol), 7-oxabenzonorbornadiene (0.4 mmol), $[Cp*CoCl_2]_2$ (5 mol %), AgSbF₆ (30 mol %), AgOAc (30 mol %), HOAc (2 equiv), DCE (2 mL), 110 °C for 12 h in 53 yield (37.1 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.70 (d, *J* = 4.8 Hz, 2H), 7.82 (s, 1H), 7.78 – 7.69 (m, 2H), 7.66 (d, *J* = 8.5 Hz, 1H), 7.56 (d, *J* = 7.7 Hz, 1H), 7.46 – 7.35 (m, 3H), 7.21 – 7.15 (m, 2H), 7.07 (d, *J* = 7.2 Hz, 1H), 6.87 (s, 1H), 2.36 (q, *J* = 7.5 Hz, 2H), 0.94 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.5, 158.3, 142.2, 137.4, 133.1, 132.5, 130.5, 129.8, 128.3, 128.2, 128.0, 127.6, 127.6, 126.8, 126.2, 126.1, 123.8, 121.6, 119.8, 118.9, 25.4, 14.4. HRMS: [M + H]⁺ calculated for C₂₄H₂₀N₃⁺: 350.1652, found: 350.1654.



3-Methyl-2,7-di(naphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (3pa)

3pa was obtained according to the procedure of **3oa** in 67% yield (61.9 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, *J* = 4.8 Hz, 2H), 8.23 (d, *J* = 8.1 Hz, 1H), 8.13 (d, *J* = 7.5 Hz, 1H), 7.82 – 7.77 (m, 4H), 7.71 (d, *J* = 8.5 Hz, 1H), 7.64 (d, *J* = 7.3 Hz, 1H), 7.50 – 7.23 (m, 7H), 7.23 – 7.16 (m, 1H), 6.93 (t, *J* = 4.8 Hz, 1H), 6.63 (d, *J* = 7.4 Hz, 1H), 2.39 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.1, 158.09, 151.6, 137.1, 135.8, 134.8, 133.2, 132.3, 131.3, 130.7, 128.4, 128.2, 127.9, 127.7, 127.66, 127.3, 126.4, 126.1, 126.0, 125.9, 125.2, 124.5, 124.0, 121.9, 121.7, 120.5, 119.1, 117.0, 115.8, 113.0, 108.6, 9.7. HRMS: [M + H]⁺ calculated for C₃₃H₂₄N₃⁺: 462.1965, found: 462.1968.



2-(6,7-Dimethoxynaphthalen-2-yl)-1-(pyrimidin-2-yl)-1H-indole (**3ab**)

3ab was obtained according to the general procedure in 48% yield (36.6 mg). white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.63 (d, J = 4.7 Hz, 2H), 8.17 (d, J = 8.1 Hz, 1H), 7.75 (s, 1H), 7.66 (d, J = 7.4 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.31 – 7.23 (m, 2H), 7.12 (d, J = 8.3 Hz, 1H), 7.08 – 7.06 (m, 3H), 6.86 (s, 1H), 3.98 (s, 3H), 3.97 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 149.8, 149.7, 140.9, 138.2, 130.0, 129.5, 129.1, 128.3, 125.9, 125.4, 124.9, 123.5, 122.2, 120.6, 117.6, 112.9, 108.2, 106.6, 106.2, 77.4, 77.1, 76.8, 55.93, 55.9. One signal is missing due to overlap. HRMS: [M + H]⁺ calculated for C₂₄H₂₀N₃O₂⁺: 382.1550, found: 382.1552.



2-(Naphtho[2,3-d][1,3]dioxol-6-yl)-1-(pyrimidin-2-yl)-1H-indole (3ac)

3ac was obtained according to the general procedure in 52% yield (38.0 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, J = 4.6 Hz, 2H), 8.16 (d, J = 8.0 Hz, 1H), 7.76 – 7.61 (m, 2H), 7.51 (d, J = 8.3 Hz, 1H), 7.31 – 7.22 (m, 2H), 7.12 (d, J = 8.2 Hz, 1H), 7.09 – 7.00 (m, 3H),

6.86 (s, 1H), 6.00 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 147.9, 147.8, 140.7, 138.2, 130.4, 130.1, 129.6, 129.5, 126.6, 126.0, 125.0, 123.5, 122.2, 120.7, 117.6, 112.9, 108.3, 104.2, 103.8, 101.1. One signal is missing due to overlap. HRMS: $[M + H]^+$ calculated for $C_{23}H_{16}N_3O_2^+$: 366.1237, found: 366.1240.

III. General procedures for the synthesis of compound 5

Reaction conditions: indole (0.2 mmol), 2-vinyloxirane (0.4 mmol), $[Cp*Co(MeCN)_3](SbF_6)_2$ (5 mol %), NaOAc (20 mol %), and DCE (2 mL) were charged into the pressure tube. The reaction mixture was stirred under N₂ at 40 °C for 12 h. After the solvent was removed under reduced pressure, the residue was purified by silica gel chromatography using PE/EA to afford the product **5**.



4-(1-(Pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5a), 2.8:1.

5a was obtained according to the general procedure in 99% yield (52.5 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.73 (d, J = 4.8 Hz, 2H), 8.25 – 8.20 (m, 1H), 7.52 (d, J = 7.7 Hz, 1H), 7.24 – 7.15 (m, 2H), 7.08 (t, J = 4.8 Hz, 1H), 6.46 (s, 1H), 5.81 (dt, J = 15.4, 6.6 Hz, 1H), 5.61 (dt, J = 15.3, 5.8 Hz, 1H), 4.22 – 3.98 (m, 2H), 3.95 – 3.90 (m, 2H), 1.71 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 158.1, 139.6, 137.0, 131.1, 129.5, 129.2, 122.7, 121.9, 119.9, 117.2, 113.7, 106.5, 63.3, 32.5. Minor: δ 139.7, 137.1, 130.3, 129.1, 129.0, 122.8, 122.0, 117.1, 113.9, 106.3, 58.6, 28.1. The NMR data agree with those in a literature report.⁵



4-(3-Methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5b), 2.7:1.

5b was obtained according to the general procedure in 98% yield (55.1 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.74 – 8.72 (m, 2H), 8.21 – 8.18 (m, 1H), 7.55 – 7.46 (m, 1H), 7.27 – 7.16 (m, 2H), 7.08 – 7.06 (m, 1H), 5.73 (dt, *J* = 15.4, 6.6 Hz, 1H), 5.52 – 5.42 (m, 1H), 4.19 – 3.88 (m, 4H), 2.29 (s, 3H), 1.41 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 158.1, 136.2, 134.1, 130.1, 129.8, 128.7, 123.0, 121.5, 118.2, 116.9, 113.8, 113.5, 63.4, 29.0, 8.86. Minor: δ 136.3, 134.6, 130.3, 129.9, 123.1, 121.6, 118.1, 116.8, 113.6, 113.4, 58.7, 25.1, 8.9. The NMR data agree with those in a literature report.⁵



4-(4-Methoxy-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5c), 3.0:1.

5c was obtained according to the general procedure in 98% yield (57.9 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.74 – 8.73 (m, 2H), 7.90 – 7.76 (m, 1H), 7.14 (t, J = 8.1 Hz, 1H), 7.11 – 7.07 (m, 1H), 6.62 (d, J = 7.9 Hz, 1H), 6.58 (s, 1H), 5.82 (dt, J = 15.4, 6.6 Hz, 1H), 5.61 (dt, J = 15.4, 5.8 Hz, 1H), 4.21 – 3.98 (m, 2H), 3.93 (s, 3H), 3.91 – 3.88 (m, 2H), 1.69 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.4, 138.3, 138.2, 131.1, 129.5, 123.47, 119.4, 117.32, 107.1, 103.2, 102.16, 63.4, 55.4, 32.5. One signal is missing due to overlap. Minor: δ 152.3, 138.4, 130.3, 129.0, 123.52, 117.27, 107.2, 103.1, 102.22, 58.6, 28.1. The NMR data agree with those in a literature report.⁵



4-(4-(Benzyloxy)-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5d), 3.2:1.

5d was obtained according to the general procedure in 87% yield (64.6 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.74 (d, J = 4.8 Hz, 2H), 7.86 – 7.81 (m, 1H), 7.50 – 7.48 (m, 2H), 7.40 – 7.36 (m, 2H), 7.33 – 7.30 (m, 1H), 7.14 – 7.08 (m, 2H), 6.68 (d, J = 7.9 Hz, 1H), 6.64 (s, 1H), 5.81 (dt, J = 15.4, 5.3 Hz, 1H), 5.62 (dt, J = 15.4, 5.8 Hz, 1H), 5.20 (s, 2H), 4.22 – 3.89 (m, 4H), 1.53 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 158.19, 151.6, 138.47, 138.2, 137.52, 131.1, 129.6, 128.5, 127.8, 127.5, 123.4, 119.8, 117.3, 107.3, 103.7, 103.5, 70.1, 63.4, 32.5. Minor: δ 151.5, 138.5, 138.3, 137.5, 130.2, 129.1, 127.47, 123.5, 117.27, 107.5, 103.8, 103.4, 58.6, 28.1. The NMR data agree with those in a literature report.⁵



Methyl 2-(4-hydroxybut-2-en-1-yl)-1-(pyrimidin-2-yl)-1H-indole-4-carboxylate (**5e**), 2.6:1. **5e** was obtained according to the general procedure in 93% yield (60.1 mg). colorless liquid;

¹H NMR (400 MHz, CDCl₃) δ 8.83 – 8.72 (m, 2H), 8.43 – 8.38 (m, 1H), 7.93 (d, J = 7.6 Hz, 1H), 7.28 – 7.21 (m, 1H), 7.20 – 7.12 (m, 2H), 5.85 (dt, J = 15.4, 6.5 Hz, 1H), 5.64 (dt, J = 15.4, 5.8 Hz, 1H), 4.25 – 3.94 (m, 7H), 1.95 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 167.9, 158.3, 157.8, 142.1, 137.76, 131.5, 129.2, 128.9, 124.8, 121.9, 120.59, 118.3, 117.7, 107.0, 63.3, 51.8, 32.5. Minor: δ 137.8, 130.6, 129.1, 128.5, 124.9, 122.0, 120.6, 118.4, 117.68, 106.8, 58.6, 28.1. HRMS: [M + H]⁺ calculated for C₁₈H₁₈N₃O₃⁺: 324.1343, found: 324.1345.



4-(4-Bromo-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5f), 2.7:1.

5f was obtained according to the general procedure in 97% yield (66.4 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.76 (d, J = 4.8 Hz, 2H), 8.18 – 8.13 (m, 1H), 7.33 (d, J = 7.7 Hz, 1H), 7.16 – 7.13 (m, 1H), 7.08 – 7.04 (m, 1H), 6.52 (s, 1H), 5.82 (dt, J = 15.4, 6.6 Hz, 1H), 5.64 (dt, J = 15.4, 5.7 Hz, 1H), 4.24 – 3.90 (m, 4H), 1.69 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 157.8, 140.66, 137.28, 131.5, 129.7, 128.8, 124.7, 123.6, 117.73, 113.7, 112.9, 106.1, 63.3, 32.5. Minor: δ 140.7, 137.3, 130.6, 129.6, 128.5, 124.8, 123.7, 117.7, 113.0, 106.0, 58.6, 28.1. The NMR data agree with those in a literature report.⁵



4-(5-Methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5g), 3.0:1.

5g was obtained according to the general procedure in 99% yield (55.3 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.73 (d, J = 4.8 Hz, 2H), 8.17 – 8.12 (m, 1H), 7.30 (s, 1H), 7.07 (t, J = 4.8 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 6.38 (s, 1H), 5.83 (dt, J = 15.4, 6.5 Hz, 1H), 5.63 (dt, J = 15.4, 5.8 Hz, 1H), 4.24 – 3.91 (m, 4H), 2.43 (s, 3H), 1.50 (1H, OH). ¹³C NMR (101 MHz, CDCl₃) δ 158.1, 158.08, 139.7, 135.3, 131.2, 130.9, 129.7, 129.5, 124.1, 119.7, 116.9, 113.7, 106.4, 63.4, 32.7, 21.4. Minor: δ 158.2, 139.8, 135.4, 131.3, 130.1, 129.4, 129.3, 124.2, 116.8, 113.8, 106.2, 58.6, 28.3. The NMR data agree with those in a literature report.⁵



4-(5-Methoxy-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5h), 3.1:1.

5h was obtained according to the general procedure in 99% yield (58.5 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, J = 4.8 Hz, 2H), 8.22 – 8.18 (m, 1H), 7.06 (t, J = 4.8 Hz, 1H), 6.98 (d, J = 2.4 Hz, 1H), 6.86 – 6.83 (m, 1H), 6.39 (s, 1H), 5.83 (dt, J = 15.4, 6.6 Hz, 1H), 5.64 (dt, J = 15.4, 5.8 Hz, 1H), 4.24 – 3.92 (m, 4H), 3.83 (s, 3H), 1.72 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.08, 158.07, 155.4, 140.5, 131.96, 131.0, 130.0, 129.6, 116.9, 115.0, 111.6, 106.5, 102.4, 63.4, 55.7, 32.8. Minor: δ 158.1, 155.44, 132.0, 130.2, 129.96, 129.1, 116.8, 115.2, 111.7, 106.4, 102.3, 58.6, 28.4. The NMR data agree with those in a literature report.⁵



Methyl 2-(4-hydroxybut-2-en-1-yl)-1-(pyrimidin-2-yl)-1H-indole-5-carboxylate (**5i**), 2.6:1. **5i** was obtained according to the general procedure in 98% yield (63.4 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.77 (d, J = 4.8 Hz, 2H), 8.29 – 8.16 (m, 2H), 7.92 – 7.89 (m, 1H), 7.18 – 7.15 (m, 1H), 6.52 (s, 1H), 5.80 (dt, J = 15.4, 6.6 Hz, 1H), 5.63 (dt, J = 15.4, 5.7 Hz, 1H), 4.24 – 3.89 (m, 7H), 1.94 – 1.87 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 158.3, 157.7, 141.27, 139.66, 131.5, 128.8, 128.7, 124.09, 123.6, 122.33, 117.8, 113.3, 106.8, 63.2, 51.9, 32.4. Minor: δ 141.3, 139.7, 130.7, 128.4, 124.1, 123.7, 122.3, 117.78, 113.5, 106.6, 58.5, 28.0. The NMR data agree with those in a literature report.⁵



4-(5-Fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5j), 2.7:1.

5j was obtained according to the general procedure in 99% yield (56.1 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.74 (d, *J* = 4.8 Hz, 2H), 8.27 – 8.15 (m, 1H), 7.20 – 7.07 (m, 2H), 6.96 – 6.91 (m, 1H), 6.41 (s, 1H), 5.82 (dt, *J* = 15.4, 6.6 Hz, 1H), 5.64 (dt, *J* = 15.4, 5.8 Hz, 1H), 4.23 – 3.91 (m, 4H), 1.67 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.9 (d, *J*_{C-F} = 237.9 Hz), 158.2, 158.0, 141.5, 133.4 (d, $J_{C-F} = 0.6$ Hz), 131.3, 129.9 (d, $J_{C-F} = 10.1$ Hz), 129.1, 117.3, 114.9 (d, $J_{C-F} = 9.1$ Hz), 110.4 (d, $J_{C-F} = 25.1$ Hz), 106.3 (d, $J_{C-F} = 4.0$ Hz), 105.0 (d, $J_{C-F} = 23.7$ Hz), 63.3, 32.7. Minor: δ 160.1, 158.19, 157.97, 157.8, 133.5, 133.45, 130.4, 129.94, 129.84, 128.8, 117.2, 115.1, 115.0, 110.6, 110.3, 106.2, 106.1, 105.2, 104.9, 58.6, 28.3. HRMS: [M + H]⁺ calculated for C₁₆H₁₅FN₃O⁺: 284.1194, found: 284.1194.



4-(5-Chloro-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5k), 2.7:1.

5k was obtained according to the general procedure in 98% yield (58.8 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.74 (d, J = 4.7 Hz, 2H), 8.20 – 8.15 (m, 1H), 7.46 (d, J = 1.1 Hz, 1H), 7.16 – 7.12 (m, 2H), 6.38 (s, 1H), 5.80 (dt, J = 15.4, 6.5 Hz, 1H), 5.63 (dt, J = 15.4, 5.8 Hz, 1H), 4.23 – 3.90 (m, 4H), 1.69 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 157.9, 141.3, 135.4, 131.4, 130.4, 129.0, 127.3, 122.7, 119.3, 117.5, 115.07, 105.8, 63.3, 32.6. Minor: δ 135.42, 130.49, 130.3, 128.7, 127.4, 122.8, 117.4, 115.2, 105.7, 58.6, 28.3. The NMR data agree with those in a literature report.⁵



4-(6-Methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (51), 3.0:1.

5I was obtained according to the general procedure in 99% yield (55.6 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.75 (d, *J* = 4.8 Hz, 2H), 8.04 – 8.01 (m, 1H), 7.39 (d, *J* = 7.9 Hz, 1H), 7.09 (t, *J* = 4.8 Hz, 1H), 7.01 (d, *J* = 7.9 Hz, 1H), 6.41 (s, 1H), 5.80 (dt, *J* = 15.4, 6.5 Hz, 1H), 5.60 (dt, *J* = 15.4, 5.8 Hz, 1H), 4.21 – 3.88 (m, 4H), 2.46 (s, 3H), 1.66 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 158.1, 138.9, 137.4, 132.57, 130.9, 129.6, 126.93, 123.4, 119.5, 117.1, 113.7, 106.3, 63.4, 32.4, 22.1. Minor: δ 139.0, 137.5, 132.6, 130.1, 129.2, 126.9, 123.5, 119.49, 117.0, 113.9, 106.2, 58.6, 28.1. HRMS: [M + H]⁺ calculated for C₁₇H₁₈N₃O⁺: 280.1444, found: 280.1448.



Methyl 2-(4-hydroxybut-2-en-1-yl)-1-(pyrimidin-2-yl)-1H-indole-6-carboxylate (**5m**), 2.8:1. **5m** was obtained according to the general procedure in 95% yield (61.4 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.90 – 8.88 (m, 1H), 8.80 (d, *J* = 4.8 Hz, 2H), 7.89 – 7.86 (m, 1H), 7.52 (d, *J* = 8.2 Hz, 1H), 7.18 – 7.15 (m, 1H), 6.50 (s, 1H), 5.82 (dt, *J* = 15.4, 6.6 Hz, 1H), 5.65 (dt, *J* = 15.4, 5.7 Hz, 1H) 4.24 – 4.02 (m, 2H), 3.97 – 3.91 (m, 5H), 1.94 – 1.87 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 168.2, 158.4, 157.7, 143.3, 136.5, 133.0, 131.6, 128.5, 124.27, 123.08, 119.4, 117.8, 115.8, 106.3, 63.2, 52.0, 32.5. Minor: δ 143.27, 136.4, 132.9, 130.8, 128.2, 124.3, 123.1, 117.7, 116.0, 106.1, 58.5, 28.2. The NMR data agree with those in a literature report.⁵



4-(6-Fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5n), 2.8:1.

5n was obtained according to the general procedure in 97% yield (54.8 mg). white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.75 (d, J = 4.8 Hz, 2H), 8.08 – 8.02 (m, 1H), 7.41 (dd, J = 8.5, 5.6 Hz, 1H), 7.13 (t, J = 4.8 Hz, 1H), 6.94 (td, J = 9.1, 2.3 Hz, 1H), 6.43 (s, 1H), 5.83 (dt, J = 15.4, 6.6 Hz, 1H), 5.64 (dt, J = 15.4, 5.8 Hz, 1H), 4.25 – 3.92 (m, 4H), 1.58 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 160.2 (d, $J_{C-F} = 237.8$ Hz), 158.2, 158.0, 140.2 (d, $J_{C-F} = 3.9$ Hz), 137.1 (d, $J_{C-F} = 12.8$ Hz), 131.1, 129.4, 125.5(d, $J_{C-F} = 1.2$ Hz), 120.2 (d, $J_{C-F} = 9.9$ Hz), 117.4, 110.1 (d, $J_{C-F} = 24.3$ Hz), 106.3, 101.3 (d, $J_{C-F} = 28.8$ Hz), 63.36, 32.67. Minor: δ 140.3, 140.21, 137.2, 137.06, 130.3, 129.0, 117.3, 110.3, 110.0, 106.1, 101.6, 101.4, 58.6, 28.3. HRMS: [M + H]⁺ calculated for C₁₆H₁₅FN₃O⁺: 284.1194, found: 284.1198.



4-(6-Chloro-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (50), 2.7:1.

50 was obtained according to the general procedure in 94% yield (56.1 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.76 (d, J = 4.8 Hz, 2H), 8.32 – 8.29 (m, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.19 – 7.10 (m, 2H), 6.42 (s, 1H), 5.82 (dt, J = 15.4, 6.6 Hz, 1H), 5.64 (dt, J = 15.4, 5.8 Hz, 1H), 4.24 – 4.01 (m, 2H), 3.95 – 3.90 (m, 2H), 1.76 – 1.59 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 157.8, 140.6, 137.3, 131.3, 129.1, 128.5, 122.4, 120.5, 117.5, 114.2, 106.2, 63.3, 32.6. One signal is missing due to overlap. Minor: δ 157.9, 137.4, 130.4, 128.7, 128.6, 122.4, 117.4, 114.3, 106.1, 58.6, 28.2. The NMR data agree with those in a literature report.⁵



4-(7-Fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5p), 2.8:1.

5p was obtained according to the general procedure in 92% yield (52.1 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.80 – 8.78 (m, 2H), 7.31 (d, J = 7.8 Hz, 1H), 7.27 – 7.21 (m, 1H), 7.08 – 7.03 (m, 1H), 6.90 – 6.86 (m, 1H), 6.47 – 6.42 (m, 1H), 5.71 – 5.58 (m, 1H), 5.44 (dt, J = 15.4, 5.8 Hz, 1H), 4.10 – 3.62 (m, 4H), 1.87 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 158.3, 149.6 (d, $J_{C-F} = 248.0$ Hz), 140.5, 132.5 (d, $J_{C-F} = 4.3$ Hz), 131.5, 128.1, 124.7 (d, $J_{C-F} = 9.1$ Hz), 121.6 (d, $J_{C-F} = 6.9$ Hz), 119.1, 115.9 (d, $J_{C-F} = 3.5$ Hz), 108.8 (d, $J_{C-F} = 19.0$ Hz), 104.8 (d, $J_{C-F} = 2.0$ Hz), 63.0, 30.6. Minor: δ 157.6, 140.7, 130.8, 127.7, 124.8, 124.66, 121.7, 121.67, 119.0, 109.0, 108.8, 104.6, 104.5, 58.3, 26.2. HRMS: [M + H]⁺ calculated for C₁₆H₁₅FN₃O⁺: 284.1194, found: 284.1196.



4-(7-Ethyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5q), 3.1:1.

5q was obtained according to the general procedure in 95% yield (55.9 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.80 – 8.79 (m, 2H), 7.41 (d, *J* = 7.7 Hz, 1H), 7.26 – 7.23 (m, 1H), 7.10 (t, *J* = 7.5 Hz, 1H), 7.01 (d, *J* = 7.3 Hz, 1H), 6.42 – 6.41 (m, 1H), 5.64 – 5.51 (m, 1H), 5.35 (dt, *J* = 15.4, 5.7 Hz, 1H), 4.03 – 3.45 (m, 4H), 2.30 – 2.23 (m, 2H), 1.93 (1H, OH), 0.94 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 158.4, 139.7, 136.0, 131.1, 129.7, 128.4, 128.0, 122.97, 121.5, 119.5, 118.1, 104.2, 63.0, 30.7, 25.7, 14.0. Minor: δ 159.1, 140.0, 136.1, 130.5, 129.71, 128.03, 127.9, 123.0, 121.6, 119.4, 104.0, 58.2, 26.2. The NMR data agree with those in a literature report.⁵



4-(1-(5-Fluoropyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (5r), 2.8:1.

5r was obtained according to the general procedure in 99% yield (56.1mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.61 (s, 2H), 8.15 – 8.11 (m, 1H), 7.56 – 7.48 (m, 1H), 7.24 – 7.16 (m, 2H), 6.46 (s, 1H), 5.82 (dt, *J* = 15.4, 6.5 Hz, 1H), 5.63 (dt, *J* = 15.4, 5.8 Hz, 1H), 4.23 – 3.87 (m, 4H), 1.53 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 155.2 (d, *J*_{C-F} = 206.0 Hz), 153.9 (d, *J*_{C-F} = 52.8 Hz), 145.8 (d, *J*_{C-F} = 21.6 Hz), 139.5, 136.99, 131.2, 129.2, 129.1, 122.8, 122.0, 120.0, 113.3, 106.4, 63.3, 32.3, 28.0. Minor: δ 153.6, 146.0, 145.8, 139.6, 137.0, 130.4, 129.0, 128.9, 122.9, 122.1, 113.5, 106.2, 58.6, HRMS: [M + H]⁺ calculated for C₁₆H₁₅FN₃O⁺: 284.1194, found: 284.1198.



4-(2-(Pyridin-2-yl)phenyl)but-2-en-1-ol (7a), 1.8:1

7a was obtained according to the general procedure in 80% yield (36.4 mg). colorless liquid;

¹H NMR (400 MHz, CDCl₃) δ 8.67 – 8.66 (m, 1H), 7.81 – 7.67 (m, 1H), 7.38 – 7.23 (m, 6H), 5.68 (dt, *J* = 15.3, 6.5 Hz, 1H), 5.42 (dt, *J* = 15.3, 5.8 Hz, 1H), 4.01 – 3.45 (m, 4H), 2.02 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 159.8, 149.1, 140.3, 137.8, 136.3, 131.4, 130.2, 130.1, 129.9, 128.5, 126.4, 124.2, 121.8, 63.3, 36.0. Minor: δ 160.0, 149.0, 140.1, 138.3, 136.6, 131.2, 130.0, 129.8, 129.1, 128.7, 126.3, 124.4, 121.9, 58.0, 31.1. The NMR data agree with those in a literature report.⁵

4-(Benzo[h]quinolin-10-yl)but-2-en-1-ol (7b), 1.7;1

7b was obtained according to the general procedure in 52% yield (26.0 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 9.08 – 8.93 (m, 1H), 8.14 – 8.12 (m, 1H), 7.80 – 7.77 (m, 2H), 7.67 – 7.52 (m, 3H), 7.48 – 7.44 (m, 1H), 6.23 (dt, *J* = 15.4, 6.5 Hz, 1H), 5.99 – 5.66 (m, 1H), 4.78-4.03 (m, 4H), 1.31 (1H, OH). ¹³C NMR (101 MHz, CDCl₃) δ 148.2, 147.3, 140.4, 135.7, 135.5, 134.2, 130.8, 129.2, 128.93, 128.9, 128.0, 127.6, 127.4, 125.6, 120.8, 64.0, 41.0. Minor: δ 148.3, 147.2, 140.6, 135.5, 135.4, 133.7, 130.5, 129.3, 129.0, 127.6, 127.5, 127.4, 125.6, 120.9, 59.2, 26.2. HRMS: $[M + H]^+$ calculated for $C_{17}H_{16}NO^+$: 250.1226, found: 250.1229.



6-(4-Hydroxybut-2-en-1-yl)-2H-[1,2'-bipyridin]-2-one (7c), 3.2:1

7c was obtained according to the general procedure in 78% yield (37.7 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.64 – 8.63 (m, 1H), 7.91 – 7.85 (m, 1H), 7.46 – 7.30 (m, 3H), 6.53 (d, J = 9.2 Hz, 1H), 6.12 (d, J = 6.9 Hz, 1H), 5.74 – 5.32 (m, 2H), 3.97 – 3.00 (m, 4H), 2.42 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 163.9, 151.4, 149.7, 147.8, 140.3, 138.5, 133.4, 125.1, 124.4, 124.2, 119.0, 105.9, 62.6, 36.0. Minor: δ 163.7, 151.5, 149.9, 147.6, 138.7, 132.6, 125.2, 124.3, 105.6, 105.6, 57.9, 31.3. HRMS: $[M + H]^+$ calculated for C₁₄H₁₅N₂O₂⁺: 243.1128, found: 243.1129.



4-(2-(Pyrimidin-2-yl)thiophen-3-yl)but-2-en-1-ol (7d), 2.0:1

7d was obtained according to the general procedure in 27% yield (12.5 mg). colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.70 – 8.69 (m, 2H), 7.39 – 7.35 (m, 1H), 7.14 – 6.94 (m, 2H), 5.95 (dt, *J* = 15.4, 6.6 Hz, 1H), 5.81 – 5.71 (m, 1H), 4.35 – 3.99 (m, 4H), 1.34 (1H, OH). ¹³C NMR (100 MHz, CDCl₃) δ 162.6, 156.8, 142.9, 136.3, 131.6, 131.3, 129.9, 128.2, 117.8, 63.7, 32.9. Minor: δ 162.5, 156.9, 142.8, 131.4, 131.1, 128.8, 128.6, 117.9, 58.6, 28.4. The NMR data agree with those in a literature report.⁵



4,4'-(5-Methoxy-2-(pyrimidin-2-yl)-1,3-phenylene)bis(but-2-en-1-ol) (7e)

7e was obtained according to the general procedure in 77% yield (50.2 mg). yellow liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.81 – 8.80 (m, 2H), 7.31 – 7.21 (m, 1H), 6.75 – 6.64 (m, 2H), 5.62 – 5.11 (m, 4H), 3.89 – 3.86 (m, 4H), 3.81 (s, 3H), 3.23 – 3.08 (m, 4H), 2.66 – 2.49 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 167.5, 159.8, 157.0, 140.02, 139.9, 131.3, 130.3, 129.5, 119.0, 113.1, 112.8, 63.1, 55.3, 36.7. Minor: δ 167.6, 159.7, 157.1, 156.9, 140.1, 140.0, 131.4, 130.4, 130.1, S17 119.1, 113.2, 63.0, 57.9, 57.8, 36.74, 31.8. HRMS: $[M + H]^+$ calculated for $C_{19}H_{23}N_2O_3^+$: 327.1703, found: 327.1706.



4,4'-(1-(Pyrimidin-2-yl)-1H-pyrrole-2,5-diyl)bis(but-2-en-1-ol) (7f)

7f was obtained according to the general procedure in 93% yield (53.5 mg). yellow liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.76 – 8.74 (m, 2H), 7.21 (t, J = 4.8 Hz, 1H), 6.02 – 5.88 (m, 2H), 5.69 – 5.24 (m, 4H), 4.07 – 4.04 (m, 1H), 3.89 – 3.87 (m, 3H), 3.55 – 3.50 (m, J = 13.5, 5.7 Hz, 4H), 2.06 – 2.00 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 158.4, 132.3, 130.2, 130.0, 129.6, 129.3, 118.7, 108.6, 63.2, 30.8. Minor: δ 157.8, 132.5, 132.4, 118.6, 108.8, 108.5, 108.4, 58.3, 58.2, 30.9, 26.5, 26.5. HRMS: [M + H]⁺ calculated for C₁₆H₂₀N₃O₂⁺: 286.1550, found: 286.1552.

IV. Mechanistic Studies

1. The experiment of H/D exchange

(a) *N*-pyrimidyl indole (0.2 mmol), $[Cp*CoCl_2]_2$ (5 mol %), AgSbF₆ (30 mol %), CD₃COOD (0.4 mmol), and DCE (2 mL) were charged into the pressure tube. The reaction mixture was stirred under N₂ at 50 °C for 12 h. After the solvent was removed under reduced pressure, the residue was purified by silica gel chromatography using PE/EA. The ratio of H/D was determined on the basis of ¹H NMR analysis.





(b) *N*-pyrimidyl indole (0.2 mmol), 7-oxabenzonorbornadiene (0.4 mmol), $[Cp*CoCl_2]_2$ (5 mol %), AgSbF₆ (30 mol %), CD₃COOD (0.4 mmol), and DCE (2 mL) were charged into the pressure tube. The reaction mixture was stirred under N₂ at 50 °C for 1 h. After the solvent was removed under reduced pressure, the residue was purified by silica gel chromatography using PE/EA. The ratio of H/D was determined on the basis of ¹H NMR analysis.

 $\begin{array}{c} \begin{array}{c} & & \\$

Z 8.6109 8.5991 8.5991 7.7878 7.77878 7.77878 7.77864 7.77864 7.77664 7.77664 7.77664 7.77664 7.77664 7.77664 7.77664 7.73239





An equimolar mixture of acetanilide **1i** (0.1 mmol) and **1h** (0.1 mmol), 7-oxabenzonorbornadiene (0.2 mmol), $[Cp*CoCl_2]_2$ (5 mol %), AgSbF₆ (30 mol %), HOAc (0.4 mmol), and DCE (2.0 mL) were charged into a pressure tube under N₂. The reaction mixture was stirred at 50 °C for 12 h. The solvent was rapidly removed under reduced pressure and the residue was purified by silica gel chromatography using PE/EA to afford the mixed product. The yield ratio (**3ia/3ha** = 2.3:1) was determined on the basis of ¹H NMR analysis.



V. References

[1] Ackermann, L.; Lygin, A. V. Org. Lett., **2011**, *13*, 3332.

[2]) Lautens, M.; Fagnou, K.; Yang, D. J. Am. Chem. Soc. 2003, 125, 14884.

[3] Yoshino, T.; Ikemoto, H., Matsunaga, S.; Kanai, M. Angew. Chem., Int. Ed. 2013, 52, 2207.

[4] Yu, D.-G.; Gensch, T.; Azambuja, F.; Vá squez-Cé spedes, S.; Glorius, F. *J Am Chem Soc* 2014, 136, 17722.

[5] Yu, S.; Li, X. Org. Lett. 2014, 16, 1200.

VI. NMR Spectra

3aa



195 185 175 165 155 145 135 125 115 105 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 fl (ppm)



3ba

195 185 175 165 155 145 135 125 115 105 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 fl (ppm)

S23



S24

- 5.2569 $\begin{array}{c} \begin{array}{c} 8.6113 \\ 8.5993 \\ 7.5120 \\ 7.4254 \\ 7.3037 \\ 7.3037 \\ 7.1057 \\ -7.0383 \\ 7.0383 \\ 7.67511 \\ 6.7511 \end{array}$ QBn 6.5 6.0 5.5 5.0 4.5 4.0 f1 (ppa) 2.02月 3.00日 1.02日 1.021 10.0 9.5 9.0 8.5 8.0 7.0 7.5 3.5 3.0 2.5 0.0 2.0 1.5 1.0 0.5 - 152.2939 - 158.3108 -70.1319 OBn

3da

195 185 175 165 155 145 135 125 115 105 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 fl (ppm)



3ea



3fa



195 185 175 165 155 145 135 125 115 105 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 f1 (ppm)

S28



3ha



190 185 180 175 170 165 160 155 150 145 140 135 130 125 120 115 110 105 100 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 f1 (ppm)

3ia



3ja



195 185 175 165 155 145 135 125 115 105 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 f1 (ppm)



185 175 165 155 145 135 125 115 105 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 fl (ppm)







195 185 175 165 155 145 135 125 115 105 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 -5 fl (ppm)



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 f1 (ppm)

S37



3ab



185 175 165 155 145 135 125 115 105 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 -5 Fl (ppm)

S39



5a



5b



5c



5d



5e



5f



5g



5h



5i



S49



5k







5m



5n



50



^{175 170 165 160 155 150 145 140 135 130 125 120 115 110 105 100 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5} fl (ppm)



 $\int 2.2691$ $\int 2.2516$ - 1.9255 $\left\{\begin{array}{l} 8.8088\\ 8.7375\\ 7.2375\\ 7.2375\\ 7.2036\\ 7.2036\\ 7.01058\\$ 0.9581
0.9581
0.9394
0.9206
0.9206



5r







7b

$\left\{ \begin{array}{l} 8.6439\\ 8.6362\\ \mathbb{Z}7.8501\\ 7.8516\\ 7.3192\\ 7.3192\\ 7.3192\\ 6.5384\\ -6.1151\\ -6.1151\\ -6.1151\\ -6.1151\\ 7.3058\\ 7.3058\\ 7.39627\\ 7.39627\\ 7.39627\\ 7.39628\\ 7.39068\\ -2.9866\\ -2.9866\\ -2.4202 \end{array} \right.$





7c



7d



7e



7f